Biontech/Pfizer’s corona vaccine is highly effective in young children between the ages of six months and five years when administered in three doses, according to study data presented on Monday. Accordingly, the manufacturers tested the vaccine in a triple dose of three micrograms each, which corresponds to a tenth of the dose for adults. According to initial estimates, the effectiveness was 80.3 percent and is therefore high.
Pfizer boss Albert Bourla spoke of “encouraging” results. The company is working on being able to quickly submit applications for approval of the vaccine for the working group to the regulatory authorities worldwide. According to Biontech boss Ugur Sahin, an application for approval will be submitted to the European Medicines Agency (EMA) in the coming weeks; the application process in the USA has been running since February.